Financial Lp Hrt Sells 225,191 Shares of Clearmind Medicine (NASDAQ:CMND) Stock

Posted by Max Byerly on Jun 14th, 2026

Clearmind Medicine Inc. (NASDAQ:CMND – Get Free Report) major shareholder Financial Lp Hrt sold 225,191 shares of the business’s stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $0.12, for a total transaction of $27,022.92. Following the transaction, the insider owned 1,838,075 shares of the company’s stock, valued at $220,569. This represents a 10.91% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Financial Lp Hrt also recently made the following trade(s):

On Wednesday, June 10th, Financial Lp Hrt bought 2,159,052 shares of Clearmind Medicine stock. The shares were acquired at an average price of $0.15 per share, with a total value of $323,857.80.

Clearmind Medicine Price Performance

NASDAQ CMND opened at $3.34 on Friday. The company has a market capitalization of $3.41 million, a PE ratio of -0.02 and a beta of 0.64. The company has a fifty day moving average of $6.22 and a 200 day moving average of $16.92. Clearmind Medicine Inc. has a 1 year low of $2.10 and a 1 year high of $524.00.

Clearmind Medicine (NASDAQ:CMND – Get Free Report) last posted its earnings results on Thursday, March 12th. The company reported ($33.20) earnings per share (EPS) for the quarter.

Analysts Set New Price Targets

Separately, Wall Street Zen raised shares of Clearmind Medicine to a “sell” rating in a report on Saturday, May 23rd.

Check Out Our Latest Report on Clearmind Medicine

About Clearmind Medicine

(Get Free Report)

Clearmind Medicine, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel psychoplastogen-based therapeutics for neuropsychiatric and neurodegenerative disorders. The company leverages a proprietary chemistry platform to design small-molecule compounds that promote rapid and sustained neural plasticity without the hallucinogenic effects typically associated with psychedelic agents. By targeting fundamental mechanisms of synaptic growth and repair, Clearmind aims to address conditions ranging from mood and anxiety disorders to cognitive impairment in dementia.

Clearmind’s pipeline includes multiple preclinical and early clinical candidates.